Your browser doesn't support javascript.
loading
Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
White, C Michael; Weisman, Nissen; Dalo, Joseph.
Afiliação
  • White CM; Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.
  • Weisman N; Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.
  • Dalo J; Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.
Ann Pharmacother ; 57(9): 1062-1075, 2023 09.
Article em En | MEDLINE | ID: mdl-36635883
ABSTRACT

OBJECTIVE:

To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer. DATA SOURCES PubMed search from inception to March 11, 2022, using the terms anxiety, depression, psychedelics, psilocybin, lysergic acid, methylenedioxymethamphetamine, or ayahuasca. STUDY SELECTION AND DATA EXTRACTION Studies assessing patients with cancer receiving psychedelics for the treatment of anxiety or depression. DATA

SYNTHESIS:

Five unique randomized, double-blind, placebo-controlled trials were conducted. Significant reductions were found in 2 trials with 2 anxiety scales (State-Trait Anxiety Inventory-State, State-Trait Anxiety Inventory-Trait) and in 1 trial with 2 additional anxiety scales (Hamilton Rating Scale-Anxiety, Hospital Anxiety and Depression Scale-Anxiety). Significant reductions were found in 2 trials in 2 depression scales (Hospital Anxiety and Depression Scale-Depression, Beck Depression Inventory) and in 1 trial with an additional depression scale (Hamilton Rating Scale-Depression). Two studies assessed for clinically relevant reductions in anxiety and depression scores, and they occurred much more commonly in psychedelic-treated patients than those given placebo. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE There is a new potential option for treating patients with anxiety and depression along with cancer, which is important given the generally lackluster benefits with traditional antidepressants. Only a few sessions may also provide benefits extending out for 6 to 12 months and possibly beyond that. However, the studies were small, had many methodological limitations, and there were increases in blood pressure and heart rate.

CONCLUSIONS:

Psychedelics have a unique mechanism of action that might be well suited for treating anxiety and depression associated with cancer. This offers new promise for patients who are not being sufficiently treated with current antianxiety or antidepressant medications.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: N-Metil-3,4-Metilenodioxianfetamina / Alucinógenos / Neoplasias Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Ann Pharmacother Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: N-Metil-3,4-Metilenodioxianfetamina / Alucinógenos / Neoplasias Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Ann Pharmacother Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos